Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)

Glycogen Storage Disease Type III Clinical Trial

Official title:
Clinical Survey Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)

Status Completed

Clinical Trial Summary

The primary objective of this study is to evaluate potential biomarkers of GSD III.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04574830
Study type	Observational
Source	Ultragenyx Pharmaceutical Inc
Contact
Status	Completed
Phase
Start date	November 23, 2020
Completion date	June 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04990388` - Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)	Phase 1/Phase 2
Completed	`NCT02054832` - Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch	N/A
Terminated	`NCT05196165` - Clinical Survey Study to Assess Physical Function and the Incidence of Hypoglycemia in Participants With Glycogen Storage Disease Type III
Active, not recruiting	`NCT02635269` - Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy	N/A
Completed	`NCT02448667` - Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies	N/A
Withdrawn	`NCT02385162` - Biomarker for Glycogen Storage Diseases (BioGlycogen)